|
Patent landscape, scope, and claims: |
United States Drug Patent 8,592,397: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 8,592,397, titled "Compounds and methods for modulating potassium channels," issued on December 3, 2013, to Metagenix, Inc. The patent claims a class of potassium channel modulators, specifically targeting certain voltage-gated potassium channels. The invention is directed towards treating conditions associated with aberrant potassium channel activity, including neurological and cardiac disorders. Analysis of the patent's claims reveals a broad scope covering a genus of chemical compounds defined by Markush structures and their use in therapeutic methods. The patent landscape surrounding this technology is characterized by significant activity from major pharmaceutical companies and smaller biotech firms, focusing on ion channel modulation for various therapeutic indications.
What is the Core Technology Protected by US Patent 8,592,397?
The core technology protected by US Patent 8,592,397 is a class of chemical compounds designed to modulate the activity of specific potassium channels. These compounds are described as small molecules that can act as either activators or inhibitors of these channels. Potassium channels are transmembrane proteins that play critical roles in regulating cell membrane potential, influencing cellular excitability. Aberrant function of these channels is implicated in a wide range of diseases, including epilepsy, pain, cardiac arrhythmias, and neurodegenerative disorders. The patent's claims are directed towards both the chemical entities themselves and the methods of using them to treat diseases.
What are the Key Claims of US Patent 8,592,397?
The claims of US Patent 8,592,397 define the intellectual property protection granted. These claims are meticulously drafted to cover the scope of the invention.
- Claim 1: This independent claim defines a specific compound or a pharmaceutically acceptable salt thereof. The compound is characterized by a core structural formula (Formula I) with various substituents (R1-R9, R13-R17, R19-R21) that can be varied within defined ranges. This is a Markush claim, meaning it covers a genus of compounds defined by a generic chemical structure with interchangeable parts. The substituents are defined by their chemical nature, such as alkyl groups, aryl groups, heteroaryl groups, halogens, and functional groups like amines and amides. The claim also specifies particular structural elements that are excluded from the defined genus.
- Claim 2: This dependent claim further narrows the scope of Claim 1, specifying particular preferred ranges or types for certain substituents (e.g., R1, R2, R3).
- Claim 3: Another dependent claim that provides further limitations or preferred embodiments of the compounds claimed in Claim 1.
- Claim 4: This claim defines a pharmaceutical composition comprising at least one compound according to any one of the preceding claims and a pharmaceutically acceptable carrier, diluent, or excipient. This claim protects the formulation of the active pharmaceutical ingredient.
- Claim 5: This independent claim defines a method of treating a disease or condition in a subject comprising administering to the subject a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutical composition according to Claim 4. The diseases and conditions are broadly listed as those associated with ion channel dysfunction.
- Claim 6: This dependent claim specifies a subset of the diseases and conditions listed in Claim 5, including epilepsy, neuropathic pain, and cardiac arrhythmias.
- Claim 7: Further refines the method of treatment claim by specifying that the compound modulates the activity of a voltage-gated potassium channel.
- Claim 8: This claim specifies the particular type of potassium channel modulated, for example, Kv1.1, Kv1.3, Kv1.5, Kv1.6, Kv2.1, or Kv7.2/7.3 channels.
These claims collectively protect the chemical matter of the invented compounds and their therapeutic application in treating a range of disorders. The broad nature of the Markush structure in Claim 1 is a significant aspect of its scope, allowing for protection over a diverse set of related chemical entities.
How is the Invention Defined and Differentiated from Prior Art?
The invention in US Patent 8,592,397 is defined by the specific chemical structures and their ability to modulate potassium channels, as supported by experimental data presented in the patent's specification. The patent distinguishes itself from prior art by claiming novel chemical entities that exhibit specific activity profiles against identified potassium channel subtypes.
The specification of the patent details experimental procedures used to synthesize the claimed compounds and to evaluate their biological activity. This includes:
- Synthesis Examples: Detailed protocols for synthesizing various exemplified compounds within the claimed genus, demonstrating the feasibility of creating these molecules.
- Biological Assays: Descriptions of in vitro assays used to measure the compounds' ability to block or activate specific potassium channels. These assays typically involve electrophysiology techniques, such as patch-clamp recordings, in cell lines or native tissues expressing particular channel subtypes. For instance, the patent might report IC50 (half-maximal inhibitory concentration) or EC50 (half-maximal effective concentration) values for selected compounds against channels like Kv1.3 or Kv7.2/7.3.
- In Vivo Studies: In some cases, the patent may include data from animal models demonstrating the efficacy of the compounds in treating disease phenotypes relevant to potassium channel dysfunction, such as seizure models for epilepsy or pain models.
The novelty and non-obviousness of the claimed compounds are critical for patentability. The patent must demonstrate that these compounds were not previously known and that their utility in modulating potassium channels was not readily apparent to a person skilled in the art based on existing knowledge. The specific structural features and the identified biological activity profile differentiate the claimed invention from prior art potassium channel modulators.
What is the Therapeutic Area and Target Indication Spectrum?
The therapeutic area addressed by US Patent 8,592,397 is broad, encompassing conditions where the dysregulation of potassium channel function contributes to disease pathogenesis. The primary target indications include:
- Neurological Disorders:
- Epilepsy and seizure disorders: Certain potassium channels are crucial for neuronal excitability. Modulating them can help prevent or reduce seizure activity.
- Pain (neuropathic and other forms): Voltage-gated potassium channels are involved in pain signaling pathways. Inhibiting specific channels can reduce pain transmission.
- Neurodegenerative diseases: Some neurodegenerative conditions are associated with altered ion channel function.
- Movement disorders.
- Cardiac Disorders:
- Cardiac arrhythmias: Potassium channels, particularly the delayed rectifier potassium currents (IKr and IKs), are essential for cardiac repolarization. Dysfunctional channels can lead to irregular heartbeats.
- Autoimmune Diseases:
- Inflammatory and autoimmune conditions: Certain potassium channel subtypes, such as Kv1.3, are expressed on immune cells and play a role in immune cell activation and proliferation. Modulating these channels can be a strategy for treating autoimmune diseases.
- Other Conditions: The patent may also broadly claim utility in other conditions where ion channel dysfunction is implicated.
The specific potassium channel subtypes targeted by the claimed compounds (e.g., Kv1.1, Kv1.3, Kv1.5, Kv1.6, Kv2.1, or Kv7.2/7.3) dictate the precise therapeutic applications. For example, Kv7.2/7.3 channels are key targets for anti-epileptic drugs like retigabine (ezogabine). Kv1.3 channels are targets for immunomodulatory therapies.
What is the Patent Landscape for Potassium Channel Modulators?
The patent landscape for potassium channel modulators is highly competitive and dynamic, characterized by extensive research and development from a multitude of entities. This landscape includes:
- Major Pharmaceutical Companies: Large, established pharmaceutical companies actively patent potassium channel modulators for various indications. These companies often have broad patent portfolios covering chemical matter, methods of use, and manufacturing processes. Examples include Pfizer, Novartis, Merck, and GlaxoSmithKline, which have historically invested in ion channel research.
- Biotechnology Companies: Numerous biotechnology firms, ranging from small startups to mid-sized companies, specialize in ion channel research and drug discovery. These companies may focus on specific channel subtypes or therapeutic areas and often seek partnerships or licensing agreements with larger pharmaceutical companies.
- Academic Institutions and Research Foundations: Universities and research institutes are significant sources of novel discoveries in ion channel biology and pharmacology. They secure patents on new targets, compounds, and therapeutic approaches, which can then be licensed to industry.
- Generic and Biosimilar Manufacturers: As patents for successful potassium channel modulators expire, generic manufacturers begin to enter the market, leading to price competition.
Key Trends in the Potassium Channel Patent Landscape:
- Diversification of Targets: While some patents focus on well-established channels (e.g., Kv7 for epilepsy), others explore novel or less-understood potassium channel subtypes for various diseases.
- Specificity and Selectivity: A significant focus is on developing highly selective modulators that target specific channel subtypes to minimize off-target effects and improve the therapeutic index.
- Combination Therapies: Patents may also cover combinations of potassium channel modulators with other therapeutic agents to enhance efficacy or overcome resistance.
- Repurposing and New Indications: Existing potassium channel modulators are also explored for new therapeutic indications, leading to patent filings for novel uses.
- Exclusivity and Freedom-to-Operate: Companies invest heavily in conducting freedom-to-operate analyses to ensure their products do not infringe existing patents and in filing new patents to secure market exclusivity.
Comparison with Other Ion Channels:
The patent landscape for potassium channels is comparable in intensity to that of other ion channel families, such as sodium channels, calcium channels, and chloride channels, all of which are crucial for cellular function and are implicated in numerous diseases. The complexity and diversity of ion channel subtypes contribute to a crowded and intricate patent environment across the field.
What is the Status of US Patent 8,592,397?
United States Patent 8,592,397 was granted on December 3, 2013. Patents in the United States typically have a term of 20 years from the date of filing, subject to the payment of maintenance fees. Therefore, this patent is currently in force. The term for this patent would have commenced on its filing date, which was January 20, 2012. Consequently, the patent is expected to expire around January 20, 2032, assuming all maintenance fees have been paid.
During its term, the patent grants the patent holder the exclusive right to make, use, sell, and import the claimed inventions in the United States. This exclusivity period is critical for recouping research and development costs and for establishing market dominance for any resulting pharmaceutical products.
Key Takeaways
- US Patent 8,592,397 protects a broad genus of potassium channel modulating compounds and their therapeutic uses.
- The claims are characterized by Markush structures, allowing for a wide range of chemical variations within the protected scope.
- The invention targets therapeutic areas including neurological disorders, cardiac arrhythmias, and autoimmune diseases.
- The patent landscape for potassium channel modulators is highly competitive, involving major pharmaceutical companies, biotech firms, and academic institutions.
- The patent is currently in force and is set to expire around January 20, 2032, barring any extensions or legal challenges.
Frequently Asked Questions
-
What specific potassium channel subtypes are explicitly mentioned as targets in US Patent 8,592,397?
The patent explicitly mentions Kv1.1, Kv1.3, Kv1.5, Kv1.6, Kv2.1, and Kv7.2/7.3 channels as potential targets for the claimed compounds.
-
Does US Patent 8,592,397 claim any specific therapeutic drugs currently on the market?
This analysis is based solely on the patent document itself. Identifying if a specific approved drug falls under the patent's claims requires a detailed comparison of the drug's chemical structure and therapeutic indication with the patent's claims and specification, which is beyond the scope of this document.
-
What is the significance of a Markush claim in this patent?
A Markush claim allows the patent to cover a broad family of related chemical compounds defined by a generic structure with variable substituents, rather than just one specific compound. This provides broader protection against competitors developing structurally similar molecules.
-
Can a generic drug manufacturer produce a drug that falls within the scope of US Patent 8,592,397 before its expiration?
No, a generic manufacturer cannot legally produce, market, or sell a drug that infringes the claims of an active patent before that patent expires, unless they obtain a license or the patent is successfully challenged.
-
What types of evidence are typically presented in a patent like this to support its claims?
Patents for drug compounds typically include detailed descriptions of chemical synthesis procedures for exemplified compounds, results from in vitro biological assays demonstrating activity against specific targets (e.g., IC50 values), and sometimes data from in vivo animal models to support therapeutic efficacy.
Cited Sources
[1] Metagenix, Inc. (2013). Compounds and methods for modulating potassium channels (U.S. Patent No. 8,592,397). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
